Abstract
This study aims to test the predictive power of gene expression data derived from NIHs database dbEST, which collects gene expression results from a large number and variety of DNA array experiments. The motivation of this study is to make comparable experimental studies, which are usually performed only for one or a few tissues or organs, with a wide variety of other tissues. Confirmation of a good predictive power of dbEST would put a number of interesting and partially surprising recent findings, solely based on data mining, on a more solid basis than available so far. The expression of nine genes (eIF4E, DDX6, HAT1, USP28, HSP90β, PKM2, PLK1, COX2 and OPN) plus two calibration genes in paired normal and cancer colon tissues of eight individual patients was investigated by quantitative RT-PCR and compared with the predictions made by the data - base. GUS and β-actin reveal only little variation among different patients, making them good internal calibration standards. In normal colon tissue, data mining correctly predicts the expression of all nine genes, which covers two orders of magnitude. In cancer, dbEST is somewhat less precise, but still valuable for the comparison with clinical results.
Keywords: Gene Expression, Colon, Cancer Patients, dbEST, Osteopontin (OPN), Cyclooxygenase 2 (COX2), Histone acetyl transferase
Current Pharmaceutical Biotechnology
Title: The Database dbEST Correctly Predicts Gene Expression in Colon Cancer Patients
Volume: 9 Issue: 6
Author(s): M. Radeva, T. Hofmann, B. Altenberg, H. Mothes, K. K. Richter, B. Pool-Zobel and K. O. Greulich
Affiliation:
Keywords: Gene Expression, Colon, Cancer Patients, dbEST, Osteopontin (OPN), Cyclooxygenase 2 (COX2), Histone acetyl transferase
Abstract: This study aims to test the predictive power of gene expression data derived from NIHs database dbEST, which collects gene expression results from a large number and variety of DNA array experiments. The motivation of this study is to make comparable experimental studies, which are usually performed only for one or a few tissues or organs, with a wide variety of other tissues. Confirmation of a good predictive power of dbEST would put a number of interesting and partially surprising recent findings, solely based on data mining, on a more solid basis than available so far. The expression of nine genes (eIF4E, DDX6, HAT1, USP28, HSP90β, PKM2, PLK1, COX2 and OPN) plus two calibration genes in paired normal and cancer colon tissues of eight individual patients was investigated by quantitative RT-PCR and compared with the predictions made by the data - base. GUS and β-actin reveal only little variation among different patients, making them good internal calibration standards. In normal colon tissue, data mining correctly predicts the expression of all nine genes, which covers two orders of magnitude. In cancer, dbEST is somewhat less precise, but still valuable for the comparison with clinical results.
Export Options
About this article
Cite this article as:
Radeva M., Hofmann T., Altenberg B., Mothes H., Richter K. K., Pool-Zobel B. and Greulich O. K., The Database dbEST Correctly Predicts Gene Expression in Colon Cancer Patients, Current Pharmaceutical Biotechnology 2008; 9 (6) . https://dx.doi.org/10.2174/138920108786786330
DOI https://dx.doi.org/10.2174/138920108786786330 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Hypoxia on Cytochrome P450 Activity and Expression
Current Drug Metabolism Computational Drug Repositioning for Cancer Therapeutics
Current Topics in Medicinal Chemistry Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design Anti-Interleukin-6 Therapy for Crohns Disease
Current Pharmaceutical Design Inhalation Delivery of Protein Therapeutics
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Tumor Activity and Underlying Mechanism of Phomoxanthone B in MCF7 Cells
Anti-Cancer Agents in Medicinal Chemistry Experimental Benefits of Sex Hormones on Vascular Function and the Outcome of Hormone Therapy in Cardiovascular Disease
Current Cardiology Reviews Oral Immune Regulation: A New Mode of Therapy Against Chronic Viral Infections
Recent Patents on Anti-Infective Drug Discovery Defining Cell Identity by Comprehensive Gene Expression Profiling
Current Medicinal Chemistry Evaluation of the <i>In Vivo</i> Acute Toxicity and <i>In Vitro</i> Hemolytic and Immunomodulatory Activities of the <i>Moringa oleifera</i> Flower Trypsin Inhibitor (MoFTI)
Protein & Peptide Letters Meet Our Editorial Board Member:
Recent Patents on Inflammation & Allergy Drug Discovery Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design How Real is Intention-To-Treat (ITT) Analysis in Non-Interventional Post Authorization Safety Studies? We Can Do Better
Current Drug Safety Association Between Seizures and Diabetes Mellitus: A Comprehensive Review of Literature
Current Diabetes Reviews Pleiotropic Beneficial Effects of Epigallocatechin Gallate, Quercetin and Delphinidin on Cardiovascular Diseases Associated with Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Cross-talk between Cellular Stress, Cell Cycle and Anticancer Agents: Mechanistic Aspects
Current Medicinal Chemistry - Anti-Cancer Agents Converging Perturbed Microvasculature and Microglial Clusters Characterize Alzheimer Disease Brain
Current Alzheimer Research Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase
Current Enzyme Inhibition Novel Oral Suspensions: A Review
Current Drug Delivery